## Wim van den Brink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1581475/publications.pdf

Version: 2024-02-01

66911 66343 7,627 176 42 78 citations h-index g-index papers 183 183 183 8681 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
2	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLoS Medicine, 2017, 14, e1002396.	8.4	362
3	Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017, 107, e1-e12.	2.7	295
4	Efficacy of As-Needed Nalmefene in Alcohol-Dependent Patients with at Least a High Drinking Risk Level: Results from a Subgroup Analysis of Two Randomized Controlled 6-Month Studies. Alcohol and Alcoholism, 2013, 48, 570-578.	1.6	293
5	Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ: British Medical Journal, 2003, 327, 310-0.	2.3	278
6	The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology, 2015, 29, 254-263.	4.0	211
7	Heroin on trial: Systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. British Journal of Psychiatry, 2015, 207, 5-14.	2.8	191
8	Compulsivity in obsessive–compulsive disorder and addictions. European Neuropsychopharmacology, 2016, 26, 856-868.	0.7	183
9	The Misuse of Prescription Opioids: A Threat for Europe?. Current Drug Abuse Reviews, 2015, 8, 3-14.	3.4	180
10	Recreational nitrous oxide use: Prevalence and risks. Regulatory Toxicology and Pharmacology, 2015, 73, 790-796.	2.7	163
11	Pharmacokinetics and Pharmacokinetic Variability of Heroin and its Metabolites: Review of the Literature. Current Clinical Pharmacology, 2006, 1, 109-118.	0.6	160
12	A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. Addiction, 2019, 114, 1095-1109.	3.3	160
13	European rating of drug harms. Journal of Psychopharmacology, 2015, 29, 655-660.	4.0	153
14	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug and Alcohol Dependence, 2014, 134, 158-166.	3.2	150
15	Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. Lancet Public Health, The, 2019, 4, e498-e505.	10.0	134
16	Evidence-Based Treatment of Opioid-Dependent Patients. Canadian Journal of Psychiatry, 2006, 51, 635-646.	1.9	119
17	Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology, 2016, 26, 1950-1959.	0.7	118
18	Pregabalin and the Risk for Opioid-Related Death: A Nested Case–Control Study. Annals of Internal Medicine, 2018, 169, 732.	3.9	116

#	Article	IF	CITATIONS
19	Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology, 2014, 28, 733-744.	4.0	109
20	Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. Clinical Psychology Review, 2014, 34, 531-550.	11.4	109
21	International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European Addiction Research, 2018, 24, 43-51.	2.4	108
22	Heroin-assisted Treatment (HAT) a Decade Later: A Brief Update on Science and Politics. Journal of Urban Health, 2007, 84, 552-562.	3.6	107
23	Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry,the, 2018, 5, 957-960.	7.4	94
24	Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European Neuropsychopharmacology, 2016, 26, 1941-1949.	0.7	77
25	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy, 2022, 99, 103381.	3.3	75
26	Dimensions and disorder specificity of impulsivity in pathological gambling. Addictive Behaviors, 2014, 39, 1646-1651.	3.0	73
27	Pharmacological treatments for heroin and cocaine addiction. European Neuropsychopharmacology, 2003, 13, 476-487.	0.7	69
28	Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2016, 387, 2226-2234.	13.7	65
29	Defining Compulsive Behavior. Neuropsychology Review, 2019, 29, 4-13.	4.9	64
30	Incentive Processing in Persistent Disruptive Behavior and Psychopathic Traits: A Functional Magnetic Resonance Imaging Study in Adolescents. Biological Psychiatry, 2015, 78, 615-624.	1.3	63
31	Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. PLoS ONE, 2016, 11, e0152482.	2.5	62
32	Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. Addictive Behaviors, 2015, 40, 91-95.	3.0	59
33	Efficacy and safety of sodium oxybate in alcoholâ€dependent patients with a very high drinking risk level. Addiction Biology, 2018, 23, 969-986.	2.6	59
34	Cue Reactivity Is Associated with Duration and Severity of Alcohol Dependence: An fMRI Study. PLoS ONE, 2014, 9, e84560.	2.5	58
35	Loss of brain graph network efficiency in alcohol dependence. Addiction Biology, 2017, 22, 523-534.	2.6	55
36	Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. British Journal of Psychiatry, 2021, 218, 88-94.	2.8	54

#	Article	IF	Citations
37	Heroin-assisted treatment in the Netherlands: History, findings, and international context. European Neuropsychopharmacology, 2010, 20, S105-S158.	0.7	53
38	Increased Release of Dopamine in the Striata of Young Adults With Hearing Impairment and Its Relevance for the Social Defeat Hypothesis of Schizophrenia. JAMA Psychiatry, 2014, 71, 1364.	11.0	52
39	Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods Health Psychology, 2015, 34, 677-685.	1.6	52
40	Treatment Seeking for Alcohol Use Disorders: Treatment Gap or Adequate Self-Selection?. European Addiction Research, 2016, 22, 277-285.	2.4	50
41	Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. American Journal of Psychiatry, 2018, 175, 1121-1128.	7.2	49
42	Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: A randomized placeboâ€controlled cross-over study using pharmacological fMRI. Addictive Behaviors, 2013, 38, 1509-1517.	3.0	47
43	Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatmentâ€seeking adults. Drug and Alcohol Review, 2015, 34, 683-693.	2.1	47
44	The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in Psychiatry, 2018, 9, 708.	2.6	47
45	Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. European Psychiatry, 2021, 64, e47.	0.2	47
46	Resting state connectivity in alcohol dependent patients and the effect of repetitive transcranial magnetic stimulation. European Neuropsychopharmacology, 2015, 25, 2230-2239.	0.7	46
47	Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology, 2022, 239, 15-33.	3.1	45
48	ICD-11 Gaming Disorder: Needed and just in time or dangerous andÂmuchÂtooÂearly?. Journal of Behavioral Addictions, 2017, 6, 290-292.	3.7	44
49	Potential influence of socioeconomic status on genetic correlations between alcohol consumption measures and mental health. Psychological Medicine, 2020, 50, 484-498.	4.5	44
50	Alcohol consumption and symptoms as predictors for relapse of DSM-5 alcohol use disorder. Drug and Alcohol Dependence, 2014, 140, 85-91.	3.2	43
51	Is Europe Facing an Emerging Opioid Crisis Comparable to the U.S.?. Therapeutic Drug Monitoring, 2021, 43, 42-51.	2.0	43
52	Prevalence and construct validity of compulsive buying disorder in shopping mall visitors. Psychiatry Research, 2015, 228, 918-924.	3.3	42
53	Causal Factors of Increased Smoking in ADHD: A Systematic Review. Substance Use and Misuse, 2018, 53, 432-445.	1.4	42
54	Genetic correlates of socio-economic status influence the pattern of shared heritability across mental health traits. Nature Human Behaviour, 2021, 5, 1065-1073.	12.0	41

#	Article	IF	CITATIONS
55	Reduced Frontal Brain Volume in Non-Treatment-Seeking Cocaine-Dependent Individuals: Exploring the Role of Impulsivity, Depression, and Smoking. Frontiers in Human Neuroscience, 2014, 8, 7.	2.0	36
56	Genomic relationships across psychiatric disorders including substance use disorders. Drug and Alcohol Dependence, 2021, 220, 108535.	3.2	36
57	Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. International Journal of Drug Policy, 2015, 26, 1177-1182.	3.3	35
58	White matter alterations in cocaine users are negatively related to the number of additionally (ab)used substances. Addiction Biology, 2017, 22, 1048-1056.	2.6	35
59	Survival in a population-based cohort of dementia patients: predictors and causes of mortality. International Journal of Geriatric Psychiatry, 1999, 14, 748-753.	2.7	33
60	Relationship between trait impulsivity and cortical volume, thickness and surface area in male cocaine users and non-drug using controls. Drug and Alcohol Dependence, 2014, 144, 210-217.	3.2	33
61	Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. Drug and Alcohol Dependence, 2014, 144, 70-77.	3.2	33
62	Treatment of crack-cocaine dependence with topiramate: A randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence, 2014, 138, 177-184.	3.2	32
63	Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial. Drug and Alcohol Dependence, 2019, 197, 28-36.	3.2	32
64	Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug and Alcohol Dependence, 2005, 80, 283-295.	3.2	31
65	Brain function during cognitive flexibility and white matter integrity in alcoholâ€dependent patients, problematic drinkers and healthy controls. Addiction Biology, 2015, 20, 979-989.	2.6	31
66	Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. Lancet Psychiatry, the, 2019, 6, 25-34.	7.4	30
67	The Role of Habits and Motivation in Human Drug Addiction: A Reflection. Frontiers in Psychiatry, 2014, 5, 8.	2.6	29
68	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. Drug and Alcohol Dependence, 2014, 145, 101-105.	3.2	29
69	Enhanced striatal responses during expectancy coding in alcohol dependence. Drug and Alcohol Dependence, 2014, 142, 204-208.	3.2	27
70	Persistence and desistance in heavy cannabis use: the role of identity, agency, and life events. Journal of Youth Studies, 2015, 18, 617-633.	2.3	27
71	A new nomenclature for classifying psychotropic drugs. British Journal of Clinical Pharmacology, 2017, 83, 1614-1616.	2.4	26
72	Childhood trauma exposure in substance use disorder patients with and without ADHD. Addictive Behaviors, 2017, 65, 118-124.	3.0	26

#	Article	IF	CITATIONS
73	Impact of DSM-5 Changes on the Diagnosis and Acute Treatment of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 637-643.	4.3	24
74	The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. Addictive Behaviors, 2018, 79, 24-31.	3.0	23
75	Explaining the Differences in Opioid Overdose Deaths between Scotland and England/Wales: Implications for European Opioid Policies. European Addiction Research, 2021, 27, 399-412.	2.4	23
76	The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of Psychopharmacology, 2014, 28, 633-642.	4.0	22
77	Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. Human Brain Mapping, 2015, 36, 4222-4230.	3.6	22
78	The use and helpfulness of self-management strategies for depression: The experiences of patients. PLoS ONE, 2018, 13, e0206262.	2.5	22
79	The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Emotion Processing, Reappraisal, and Craving in Alcohol Use Disorder Patients and Healthy Controls: A Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry, 2019, 10, 272.	2.6	22
80	Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. Journal of Psychiatry and Neuroscience, 2015, 40, 197-206.	2.4	21
81	Psychosocial work conditions and work stress in an innovating addiction treatment centre. Consequences for the EFQM Excellence Model. Total Quality Management and Business Excellence, 2009, 20, 267-281.	3.8	20
82	The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. Drug and Alcohol Dependence, 2016, 163, 48-54.	3.2	20
83	Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial. Journal of Psychopharmacology, 2016, 30, 616-626.	4.0	20
84	Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. Drug and Alcohol Dependence, 2017, 179, 117-123.	3.2	20
85	Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia Research, 2018, 194, 32-38.	2.0	20
86	N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research. Expert Opinion on Investigational Drugs, 2018, 27, 667-675.	4.1	20
87	Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity. Addictive Behaviors, 2011, 36, 570-575.	3.0	19
88	Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regulatory Toxicology and Pharmacology, 2014, 70, 507-513.	2.7	19
89	Differential Effects of Left and Right Prefrontal High-Frequency Repetitive Transcranial Magnetic Stimulation on Resting-State Functional Magnetic Resonance Imaging in Healthy Individuals. Brain Connectivity, 2018, 8, 60-67.	1.7	19
90	Adverse effects of GHB-induced coma on long-term memory and related brain function. Drug and Alcohol Dependence, 2018, 190, 29-36.	3.2	19

#	Article	IF	Citations
91	Post-GWAS analysis of six substance use traits improves the identification and functional interpretation of genetic risk loci. Drug and Alcohol Dependence, 2020, 206, 107703.	3.2	19
92	The relationship between socio-economic inequality and criminal victimisation: a prospective study. Social Psychiatry and Psychiatric Epidemiology, 2001, 36, 361-370.	3.1	18
93	Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology, 2015, 29, 678-687.	4.0	18
94	Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion on Drug Safety, 2015, 14, 495-504.	2.4	18
95	Integrated cognitive behavioral therapy for patients with Substance Use Disorder and Comorbid ADHD: Two case presentations. Addictive Behaviors, 2015, 45, 214-217.	3.0	18
96	Diagnosing ADHD during active substance use: Feasible or flawed?. Drug and Alcohol Dependence, 2017, 180, 371-375.	3.2	18
97	Ranking the harm of non-medically used prescription opioids in theÂUK. Regulatory Toxicology and Pharmacology, 2015, 73, 999-1004.	2.7	17
98	Emotion Processing, Reappraisal, and Craving in Alcohol Dependence: A Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry, 2019, 10, 227.	2.6	17
99	Doubt in the Insula: Risk Processing in Obsessive-Compulsive Disorder. Frontiers in Human Neuroscience, 2016, 10, 283.	2.0	15
100	Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. Pharmacogenomics, 2018, 19, 95-104.	1.3	15
101	Enhanced Amygdala-Striatal Functional Connectivity during the Processing of Cocaine Cues in Male Cocaine Users with a History of Childhood Trauma. Frontiers in Psychiatry, 2018, 9, 70.	2.6	15
102	Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. Drug and Alcohol Dependence, 2016, 168, 164-169.	3.2	14
103	The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials. European Neuropsychopharmacology, 2017, 27, 82-86.	0.7	14
104	Factors associated with victimization in dual diagnosis patients. Journal of Substance Abuse Treatment, 2018, 84, 68-77.	2.8	14
105	Increasing recreational nitrous oxide use: Should we worry? A narrative review. Journal of Psychopharmacology, 2022, 36, 943-950.	4.0	14
106	Hyperresponsiveness of the Neural Fear Network During Fear Conditioning and Extinction Learning in Male Cocaine Users. American Journal of Psychiatry, 2016, 173, 1033-1042.	7.2	13
107	Design of a syndemic based intervention to facilitate care for men who have sex with men with high risk behaviour: the syn.bas.in randomized controlled trial. BMC Infectious Diseases, 2017, 17, 398.	2.9	13
108	Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. Journal of Psychopharmacology, 2018, 32, 353-356.	4.0	13

#	Article	IF	Citations
109	Recreational use of GHB is associated with alterations of resting state functional connectivity of the central executive and default mode networks. Human Brain Mapping, 2019, 40, 2413-2421.	3.6	13
110	Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology, 2021, 52, 18-30.	0.7	13
111	Effect of GHB-use and GHB-induced comas on dorsolateral prefrontal cortex functioning in humans. NeuroImage: Clinical, 2018, 20, 923-930.	2.7	12
112	Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder. Current Opinion in Psychiatry, 2019, 32, 300-306.	6.3	12
113	Selfâ€wise, Otherâ€wise, Streetwise (SOS) training, an intervention to prevent victimization in dualâ€diagnosis patients: results from a randomized clinical trial. Addiction, 2019, 114, 730-740.	3.3	12
114	Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial. Addictive Behaviors, 2020, 103, 106228.	3.0	12
115	Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opinion on Drug Safety, 2022, 21, 83-94.	2.4	12
116	Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A metaâ€regression analysis to develop an enrichment strategy. Alcoholism: Clinical and Experimental Research, 2021, 45, 1722-1734.	2.4	12
117	Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. Neurotoxicity Research, 2021, 39, 2120-2133.	2.7	12
118	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug and Alcohol Dependence, 2021, 227, 108984.	3.2	12
119	Monitoring Opioids in Europe: The Need for Shared Definitions and Measuring Drivers of Opioid Use and Related Harms. European Addiction Research, 2022, 28, 231-240.	2.4	12
120	Self-reported cue-induced physical symptoms of craving as an indicator of cocaine dependence. American Journal on Addictions, 2015, 24, 740-743.	1.4	11
121	The role of leisure and delinquency in frequent cannabis use and dependence trajectories among young adults. International Journal of Drug Policy, 2015, 26, 143-152.	3.3	11
122	Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. Substance Use and Misuse, 2016, 51, 1905-1911.	1.4	11
123	Reactivity to social stress in ethnic minority men. Psychiatry Research, 2016, 246, 629-636.	3.3	11
124	Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders. European Addiction Research, 2020, 26, 201-210.	2.4	11
125	Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia – An individual patient data meta-analysis. European Neuropsychopharmacology, 2014, 24, 1067-1077.	0.7	10
126	Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. British Journal of Psychiatry, 2014, 204, 486-487.	2.8	10

#	Article	IF	CITATIONS
127	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. Drug and Alcohol Dependence, 2018, 188, 94-101.	3.2	10
128	Use of the Fagerström test to assess differences in the degree of nicotine dependence in smokers from five ethnic groups: The HELIUS study. Drug and Alcohol Dependence, 2019, 194, 197-204.	3.2	10
129	Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders. Journal of Dual Diagnosis, 2020, 16, 208-217.	1.2	10
130	The effect of N-acetylcysteine and working memory training on neural mechanisms of working memory and cue reactivity in regular cocaine users. Psychiatry Research - Neuroimaging, 2019, 287, 56-59.	1.8	9
131	Guideline for Screening, Diagnosis and Treatment of ADHD in Adults with Substance Use Disorders. International Journal of Mental Health and Addiction, 2014, 12, 629-647.	7.4	8
132	Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial. Drug and Alcohol Dependence, 2016, 164, 55-63.	3.2	8
133	VMAT2 gene ( <i>SLC18A2</i> ) variants associated with a greater risk for developing opioid dependence. Pharmacogenomics, 2019, 20, 331-341.	1.3	8
134	Clinical effects beyond cocaine use of sustainedâ€release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a doubleâ€blind, placeboâ€controlled randomized trial. Addiction, 2020, 115, 917-923.	3.3	8
135	Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders. European Addiction Research, 2020, 26, 191-200.	2.4	8
136	Effects of Recreational GHB Use and Multiple GHB-Induced Comas on Brain Structure and Impulsivity. Frontiers in Psychiatry, 2020, 11, 166.	2.6	8
137	Recreational N <sub>2</sub> 0 use: just laughing or really bad news?. Addiction, 2022, 117, 268-269.	3.3	8
138	Near-fatal persistent anion- and osmolal-gap acidosis due to massive gamma-butyrolactone/ethanol intoxication. Annals of Clinical Biochemistry, 2015, 52, 283-287.	1.6	7
139	Influence of Gamma-Hydroxybutyric Acid-Use and Gamma-Hydroxybutyric Acid-Induced Coma on Affect and the Affective Network. European Addiction Research, 2019, 25, 173-181.	2.4	7
140	A guide on gene prioritization in studies of psychiatric disorders. International Journal of Methods in Psychiatric Research, 2015, 24, 245-256.	2.1	6
141	Reprint of The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. Addictive Behaviors, 2018, 83, 79-86.	3.0	6
142	Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. Harm Reduction Journal, 2018, 15, 47.	3.2	6
143	Demographic and Clinical Characteristics of Regular GHB-Users with and without GHB-Induced Comas. Substance Use and Misuse, 2020, 55, 2148-2155.	1.4	6
144	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. Revista De Psiquiatrãa Y Salud Mental, 2020, , .	1.8	6

#	Article	IF	CITATIONS
145	What lessons from Europe's experience could be applied in the United States in response to the opioid addiction and overdose crisis?. Addiction, 2022, 117, 1197-1198.	3.3	6
146	High-potency cannabis and incident psychosis: correcting the causal assumption. Lancet Psychiatry, the, 2019, 6, 464-465.	7.4	5
147	Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. Neuroscience Letters, 2019, 704, 100-105.	2.1	5
148	Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 659-670.	2.2	5
149	Cognitive Impairment Following Clinical or Recreational Use of Gammahydroxybutyric Acid (GHB): A Systematic Review. Current Neuropharmacology, 2022, 20, 809-819.	2.9	5
150	Early Nonresponse in the Antipsychotic Treatment of Acute Mania. Journal of Clinical Psychiatry, 2016, 77, e1117-e1123.	2.2	5
151	Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology, 2022, 36, 1136-1145.	4.0	5
152	Wim van den Brink and colleagues reply to Des Spence and Alain Braillon. BMJ, The, 2014, 348, g2605-g2605.	6.0	4
153	Treatment Outcome of Alcohol Use Disorder Outpatients With or Without Medically Assisted Detoxification. Journal of Studies on Alcohol and Drugs, 2014, 75, 993-998.	1.0	4
154	Early developmental, temperamental and educational problems in †substance use disorder†patients with and without ADHD. Does ADHD make a difference?. Addictive Behaviors Reports, 2015, 2, 13-18.	1.9	4
155	A Comparison of Excessive Drinking, Binge Drinking and Alcohol Dependence in Ethnic Minority Groups in the Netherlands: The HELIUS Study. European Addiction Research, 2020, 26, 66-76.	2.4	4
156	Onset and Severity of Early Disruptive Behavioral Disorders in Treatment-Seeking Substance Use Disorder Patients with and without Attention-Deficit/Hyperactivity Disorder. European Addiction Research, 2020, 26, 211-222.	2.4	4
157	Contribution of Alcohol and Nicotine Dependence to the Prevalence of Depressed Mood in Different Ethnic Groups in The Netherlands: The HELIUS Study. Journal of Dual Diagnosis, 2020, 16, 271-284.	1.2	4
158	Nitrous oxide–induced reproductive risks: Should recreational nitrous oxide users worry?. Journal of Psychopharmacology, 2022, 36, 951-955.	4.0	4
159	A randomised controlled trial of outpatientversusinpatient integrated treatment of dual diagnosis patients: a failed but informative study. Mental Health and Substance Use: Dual Diagnosis, 2012, 5, 132-147.	0.5	3
160	Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. Journal of Psychopharmacology, 2015, 29, 344-348.	4.0	3
161	Safety of nalmefene for the treatment of alcohol use disorder: an update. Expert Opinion on Drug Safety, 2020, 19, 9-17.	2.4	3
162	Use characteristics and harm potential of ecstasy in The Netherlands. Drugs: Education, Prevention and Policy, 2021, 28, 107-117.	1.3	3

#	Article	IF	CITATIONS
163	Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. Journal of Psychopharmacology, 2021, 35, 537-546.	4.0	3
164	Self-Medication of ADHD Symptoms: Does Caffeine Have a Role?. Frontiers in Psychiatry, 2022, 13, 813545.	2.6	3
165	Tackling rising numbers of opioid prescriptions users. Lancet Public Health, The, 2020, 5, e139.	10.0	2
166	Effect of Methylphenidate on Resting-State Connectivity in Adolescents With a Disruptive Behavior Disorder: A Double-Blind Randomized Placebo-Controlled fMRI Study. Frontiers in Psychiatry, 2021, 12, 662652.	2.6	2
167	The effect of N-acetylcysteine and working memory training on glutamate concentrations in the dACC and rACC in regular cocaine users – A randomized proof of concept study. Neuroscience Letters, 2021, 762, 136146.	2.1	2
168	Consequences of the use of different classification systems: a comparison of the DSM-III-R and the ICD-10 for depression. International Journal of Methods in Psychiatric Research, 1999, 8, 192-203.	2.1	1
169	Does Self-medication Predict the Persistence or Rather the Recurrence of Alcohol Dependence?. JAMA Psychiatry, 2014, 71, 205.	11.0	1
170	Response to "Baclofen and alcohol use disorders: From miracle to mirage― European Neuropsychopharmacology, 2017, 27, 693-694.	0.7	1
171	Further evidence for the association of <i>GAL</i> , <i>GALR1</i> Âand <i>NPY1R</i> Âvariants with opioid dependence. Pharmacogenomics, 2020, 21, 903-917.	1.3	1
172	Science-based practice for methadone treatment: another step forward. International Journal of Public Health, 2003, 48, S15-6; discussion S25-7.	2.6	0
173	THE SDSS SCALE—A REPLY TO GONZÃŁEZâ€SAIZ. Addiction, 2007, 102, 828-829.	3.3	0
174	The Unhealthy Chicken or the Unhealthy Egg: Quitting Smoking Matters: Response to Hajek et al American Journal of Psychiatry, 2019, 176, 575-576.	7.2	0
175	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention Deficit Hyperactivity Disorder and Substance Use Disorder. Çocuk Ve Gençlik Ruh Sağlığı Dergisi / Turkish Journal of Child and Adolescent Mental Health, 2021, 28, 79-88.	0.4	0
176	Neurobiology of ADHD and comorbid substance use disorders. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY18-3.	0.0	0